ZA71.F Larimar Therapeutics Inc
- Market cap
- EUR 258M
- P/E
- -
- P/B
- 2.19x
- ROE
- -98.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ZA71.F undervalued?
Graham numberThe Graham number of Larimar Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Larimar Therapeutics Inc fundamental analysis
No fundamental analysis for Larimar Therapeutics Inc yet.
Larimar Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Full company profileLarimar Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Larimar Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -23.2M | -42.8M | -50.5M | -36.5M | -41.8M | -90.9M | -172M | -131M |
| EBITDA | -23.1M | - | - | -36.2M | -41.4M | -90.6M | -172M | -131M |
| Net Income | -23.1M | -42.5M | -50.6M | -35.4M | -36.9M | -80.6M | -166M | -125M |
| EPS | -2.51 | -2.76 | -2.86 | -0.82 | -0.84 | -1.26 | -1.99 | -1.20 |
| Balance Sheet | ||||||||
| Total Assets | 5.20M | 105M | 78.7M | 126M | 95.9M | 200M | 146M | 165M |
| Total Liabilities | 5.90M | 15.0M | 14.3M | 15.5M | 14.2M | 28.4M | 67.8M | 37.9M |
| Shareholders' Equity | -694K | 89.7M | 64.4M | 111M | 81.7M | 172M | 78.1M | 127M |
| Cash & Short-term Investments | 1.01M | 68.1M | 70.1M | 26.8M | 26.7M | 33.2M | 85.4M | 92.7M |
| Cash Flow | ||||||||
| Operating Cash Flow | -22.7M | -42.2M | -42.1M | -27.6M | -33.5M | -70.8M | -113M | -177M |
| Capital Expenditure | 83.0K | 62.0K | 333K | 100K | 164K | 515K | 91.0K | 0.00 |
| Free Cash Flow | -22.8M | -42.3M | -42.4M | -27.7M | -33.6M | -71.3M | -113M | -178M |
| Ratios | ||||||||
| ROE | - | -47.4% | -78.6% | -31.9% | -45.2% | -46.9% | -212.2% | -98.0% |
| ROA | -444.8% | -40.6% | -64.4% | -28.0% | -38.5% | -40.3% | -113.6% | -75.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Larimar Therapeutics Inc dividends
Larimar Therapeutics Inc has not paid dividends in the last 7 fiscal years.
Who owns Larimar Therapeutics Inc
- Insiders 1.19%
- Institutions 94.20%
- Public & others 4.61%
- Shares outstanding 104M
- Free float 57.9M
Larimar Therapeutics Inc company profile
- Company name
- Larimar Therapeutics Inc
- Ticker
- ZA71.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 71
- Fiscal year end
- December
- Address
- Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004
- Phone
- 844 511 9056
- Website
- larimartx.com
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Larimar Therapeutics Inc management
8- Dr. Carole S. Ben-Maimon M.D.CEO & Director · born 1959
- Mr. Michael Celano CPASecretary & CFO · born 1959
- Dr. Gopi Shankar M.B.A., Ph.D.Chief Development Officer · born 1971
- Mr. John B. Harlow Jr.President & COO · born 1976
- Mr. John BermanVice President of Finance & Administration
- Ms. Jennifer Spokes JohanssonVice President of Legal & Compliance
- Dr. Russell G. Clayton Sr., D.O.Chief Medical Officer · born 1961
- Mr. Francis Michael Conway CPAVP & Controller